Lantheus Holdings (LNTH) Stock

Why Lantheus Holdings Stock Won Big on Wednesday

BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months.

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20.

Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity.

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning.

BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products.

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024.

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.